IC Sink or Swim article9 Jun 2018 16:01
In a nutshell it explains why this share has not performed, Big Pharma is not interested in anti biotics as they are low margin mass market and Ilcaprim is no better than any other antibiotic.
Before the lynch mob arrives this is the IC view, though they balance the article talking about drug resistance they say that even with approval it will take years to get further trials and the profile of the drug raised which will cost yet more money. They say that Motif would be better if a larger player bought them out.
I am only in this for a punt. The SP has not performed and we all know why, question is whether it ever will. IC thinks not